AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3021082
Drug: Concomitant administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concomitant administration of naloxone hydrochloride and yohimbine hydrochloride
Trial: 22270205
Drug: All BTXA
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All BTXA preparations combined
Trial: 11396535
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate (RBC) 400 mg b.d. plus amoxycillin 1 g b.d. and clarithromycin 500 mg b.d. for 7 days
Trial: 11396535
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate (RBC) 400 mg b.d. plus amoxycillin 1 g b.d. and clarithromycin 500 mg b.d. for 7 days followed by 3 weeks of RBC 400 mg b.d. alone
Trial: 9935258
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg alatrofloxacin daily followed by 200 mg oral trovafloxacin daily
Trial: 11039067
Drug: 0.4% SnF2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4% SnF2 gel with 98% available Sn2+ ion, used twice daily for nine months
Trial: 347857
Drug: Combined oestrogen/androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oestrogen/androgen compound
Trial: 28091532
Drug: Ibudilast (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibudilast (50 mg b.i.d.)
Trial: 26987135
Drug: Metoprolol succinate
RxNorm normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol succinate (59.1 ± 12.1 mg/d)
Trial: 29222619
Drug: Behavioural sleep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural sleep medicine (BSM) intervention targeting physical activity and eating behaviour (10 individual sessions with a dietician and a physiotherapist).
Trial: 29222619
Drug: Behavioural sleep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural sleep medicine (BSM) intervention targeting physical activity and eating behaviour.
Trial: 17142063
Drug: Acetaminophen ER
RxNorm normalized name: acetaminophen Extended Release Oral Tablet
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen ER 1950 mg
Trial: 9710686
Drug: 0.1/0.06 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1/0.06 mg/kg r-hirudin (bolus/infusion per hour over 48 h)
Trial: 9710686
Drug: 0.2/0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2/0.1 mg/kg r-hirudin (bolus/infusion per hour over 48 h)
Trial: 9710686
Drug: 0.4/0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4/0.15 mg/kg r-hirudin (bolus/infusion per hour over 48 h)
Trial: 7859799
Drug: All dosage
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All dosage groups
Trial: 19368788
Drug: 0.1mL intradermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1mL intradermal influenza vaccine
Trial: 11504318
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (nortriptyline)
Trial: 9133547
Drug: Trimethaphan (0.3-0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethaphan (0.3-0.6 mg/min)
Trial: 9133547
Drug: Regular human
RxNorm normalized name: insulin regular human recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular human insulin (0.28 pmol x m(-2) x min(-1)) with variable rate glucose infusion
Trial: 29420073
Drug: 380 mg
RxNorm normalized name: aspirin 380 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 380 mg intramuscular injections of long‐acting naltrexone on study day 1 and at the start of study week 5
Trial: 21674691
Drug: Sequential finger
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential finger tapping task
Trial: 19413822
Drug: Nasal cannula
RxNorm normalized name: EUCALYPTUS OIL 0.15 g in 1 g / MENTHOL, UNSPECIFIED FORM 0.2 g in 1 g / ARGININE 0.1 g in 1 g TOPICAL CREAM [Slimming Detox Nasal Cannula]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal cannula oxygen administration at 2 l x min(‐1)
Trial: 19413822
Drug: Nasal cannula
RxNorm normalized name: EUCALYPTUS OIL 0.15 g in 1 g / MENTHOL, UNSPECIFIED FORM 0.2 g in 1 g / ARGININE 0.1 g in 1 g TOPICAL CREAM [Slimming Detox Nasal Cannula]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal cannula oxygen administration at 4 l x min(‐1)
Trial: 19413822
Drug: Nasal cannula
RxNorm normalized name: EUCALYPTUS OIL 0.15 g in 1 g / MENTHOL, UNSPECIFIED FORM 0.2 g in 1 g / ARGININE 0.1 g in 1 g TOPICAL CREAM [Slimming Detox Nasal Cannula]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal cannula oxygen administration at all flow rates
Trial: 12100641
Drug: Manual pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual pressure applied before intramuscular injection for 10 seconds
Trial: 12100641
Drug: Conventional injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional injection without manual pressure
Trial: 7883836
Drug: Alprazolam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (2 mg, orally)
Trial: 7968328
Drug: Nifedipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (10 mg sublingual)
Trial: 16446685
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein (40 g protein/day)
Trial: 16446685
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein (40 g protein/day)
Trial: 14609102
Drug: Pimecrolimus 1%
RxNorm normalized name: PIMECROLIMUS 1% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimecrolimus 1% ointment applied twice daily for 21 days
Trial: 14609102
Drug: Vehicle (corresponding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (corresponding vehicle ointment)
Trial: 8915143
Drug: Calcipotriol 0.005%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol 0.005% ointment
Trial: 14609102
Drug: Clobetasol-17-propionate 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobetasol-17-propionate 0.05% ointment
Trial: 2671283
Drug: CMFVP (combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMFVP (combination cyclophosphamide 60 mg/m2 orally every day for 1 year; fluorouracil 300 mg/m2 IV weekly for 1 year; methotrexate 15 mg/m2 IV weekly for 1 year; vincristine 0.625 mg/m2 IV for 10 weeks; prednisone 30 mg/m2 orally days 1 to 14, 20 mg/m2 days 15 to 28, 10 mg/m2 days 29 to 42)
Trial: 339787
Drug: fenoterol (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fenoterol (0.4 mg t.i.d. or q.i.d.)
Trial: 339787
Drug: isoproterenol (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: isoproterenol (0.15 mg t.i.d. or q.i.d.)
Trial: 31833059
Drug: 24-hour maintenance
RxNorm normalized name: cenobamate
DrugBank: Cenobamate (DB06119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 24-hour maintenance dose of magnesium sulfate (MgSO4)
Trial: 22065870
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group DMP includes individualized education and follow-up from a multidisciplinary heart failure team; a weekly education programme for 12 weeks; self-management advice; and medical follow-up.
Trial: 18805773
Drug: Diclofenac-orphenadrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac-orphenadrine infusion (Group A)
Trial: 16599097
Drug: SuperSeal (oxalate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SuperSeal (oxalate preparation)
Trial: 8403157
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam (0.5 mg.kg‐1) premedication, 10 min interval
Trial: 8403157
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam (0.5 mg.kg‐1) premedication, 20 min interval
Trial: 8403157
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam (0.5 mg.kg‐1) premedication, 30 min interval
Trial: 26818228
Drug: Cholecalciferol 4000
RxNorm normalized name: Cholecalciferol 4000 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol 4000 International Units daily for 16 weeks
Trial: 26818228
Drug: Cholecalciferol 2000
RxNorm normalized name: cholecalciferol 2000 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol 2000 International Units daily for 16 weeks
Trial: 22735040
Drug: Financial incentive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Financial incentive version of smoking cessation treatment costing $750 per success
Trial: 22735040
Drug: Medication version
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication version of smoking cessation
Trial: 22735040
Drug: Overall support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall support for all smoking cessation treatments
Trial: 20448287
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg weekly subcutaneous etanercept added to previous DMARD treatment
Trial: 20448287
Drug: Previous DMARD
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Previous DMARD therapy
Trial: 8936753
Drug: Small group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small group treatment (3-4 patients)
Trial: 8936753
Drug: Large group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large group treatment (7-8 patients)
Trial: 31472003
Drug: Intact parathyroid
RxNorm normalized name: Intact parathyroid hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intact parathyroid hormone (iPTH)
Trial: 27377073
Drug: Short-cycle therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-cycle therapy (SCT) (5 days on, 2 days off ART)
Trial: 27377073
Drug: Continuous therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous therapy (CT) (daily ART)
Trial: 15249584
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and Radiation Therapy (chemoRT)
Trial: 15249584
Drug: Chemotherapy (fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (fluorouracil and levamisole)
Trial: 11228276
Drug: Reviparin twice
RxNorm normalized name: reviparin
DrugBank: Reviparin (DB09259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reviparin twice daily
Trial: 11228276
Drug: Reviparin once
RxNorm normalized name: reviparin
DrugBank: Reviparin (DB09259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reviparin once daily
Trial: 20107201
Drug: Cyclosporine (gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (gelatin capsule microemulsion formulation)
Trial: 20107201
Drug: NR1I2 genotype
RxNorm normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NR1I2 genotype (g.‐25385C‐g.‐24381A‐g.‐205_‐200GAGAAG‐g.7635G‐g.8055C haplotype)
Trial: 17127551
Drug: Methylphenidate treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate treatment for ADHD and cocaine dependence
Trial: 12768117
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline dextran (HSD) (250 mL)
Trial: 10705267
Drug: EH 200
RxNorm normalized name: EH-301 COMPONENT PTEROSTILBENE
DrugBank: Pterostilbene (DB17939)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EH 200 group (62 patients) using EH 200 microg/dose inhaler (1 inhalation q.i.d.)
Trial: 10705267
Drug: DH group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DH group (61 patients) using DH 200 microg/dose inhaler (1 inhalation q.i.d.)
Trial: 9349931
Drug: 15-min i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-min i.v. infusion of 1 mg draflazine
Trial: 30672215
Drug: Yinqi Guiyuan
RxNorm normalized name: Guiyujin (Curcuma Longa)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yinqi Guiyuan needles therapy combined with moxibustion at Yongquan (KI 1)
Trial: 27270872
Drug: Curcumin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (500 mg/day equivalent to 70 mg curcumin)
Trial: 22014381
Drug: Immediate Zoledronic
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Immediate Zoledronic Acid (ZOL) treatment (4 mg every 6 months)
Trial: 17206439
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose ingestion (75 g) without exercise
Trial: 14979604
Drug: Adicanil (test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adicanil (test formulation)
Trial: 14979604
Drug: Commercially available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available preparation (reference formulation)
Trial: 12621741
Drug: Three times
RxNorm normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three times a day administration of carbapenems (0.5 g x 3)
Trial: 12621741
Drug: Twice a
RxNorm normalized name: Pataday Twice A Day Relief
DrugBank: Olopatadine (DB00768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice a day administration of carbapenems (0.75 g x 2)
Trial: 9818297
Drug: Amitriptyline (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (25 mg tablet) with food
Trial: 9818297
Drug: Amitriptyline (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (25 mg tablet) fasting
Trial: 25836004
Drug: Translation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Translation treatment
Trial: 25836004
Drug: Controlled tipping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled tipping treatment
Trial: 19174617
Drug: Haloperidol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (10 microg/kg) plus ondansetron (0.1 mg/kg)
Trial: 20935397
Drug: Oral montelukast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral montelukast (10 mg/day)
Trial: 10522838
Drug: Repaglinide (0.25-4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide (0.25-4.0 mg preprandially)
Trial: 10522838
Drug: Repaglinide (0.5-4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide (0.5-4.0 mg preprandially)
Trial: 7367848
Drug: Specific hyposensitization
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific hyposensitization treatment with semi-depot extracts
Trial: 29089038
Drug: N-acetylcysteine (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (1200 mg) and ascorbic acid (2 g) intravenously, administered 2 hours before, and at 10 and 18 hours after contrast infusion
Trial: 25582984
Drug: Low-dose combination
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose combination oral contraceptive (COC)
Trial: 23350584
Drug: Positive estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive estrogen receptor (ER) status
Trial: 21314437
Drug: Alcaftadine ophthalmic
RxNorm normalized name: alcaftadine ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcaftadine ophthalmic solution 0.25%
Trial: 21314437
Drug: Alcaftadine ophthalmic
RxNorm normalized name: alcaftadine ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcaftadine ophthalmic solution (various concentrations 0.05%-0.5%)
Trial: 19223168
Drug: Pre-loading with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-loading with 500 mL of 6% hetastarch intravenously
Trial: 19223168
Drug: Co-loading with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-loading with 500 mL of 6% hetastarch intravenously
Trial: 17958625
Drug: Oral erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral erythromycin
Trial: 17415637
Drug: Oral omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral omeprazole without erythromycin
Trial: 9699197
Drug: Androgen gel
RxNorm normalized name: testosterone Topical Gel [Androgel]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen gel (group A)
Trial: 9699197
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel (group P)
Trial: 8076921
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (less than one hundredth of the recommended dose of porcine calcitonin)
Trial: 9468008
Drug: Chlorthalidone 25
RxNorm normalized name: chlorthalidone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone 25 mg/day
Trial: 2676651
Drug: Chlorthalidone 25
RxNorm normalized name: chlorthalidone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone 25 mg/day + slow-release metoprolol 200 mg/day
Trial: 31187552
Drug: Behavioral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral therapy (pelvic floor muscle exercises, bladder training, fluid and constipation management)
Trial: 25797356
Drug: CPT‐11/CDDP (CPT‐11,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPT‐11/CDDP (CPT‐11, 60 mg/m²; CDDP, 30 mg/m², q2w)
Trial: 25797356
Drug: CPT‐11 (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPT‐11 (150 mg/m², q2w)
Trial: 23590571
Drug: L-selenomethionine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-selenomethionine (200 μg daily)
Trial: 16756046
Drug: Counseling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Counseling and clinical pathway for treatment of hypoglycemia
Trial: 16756046
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment for hypoglycemia
Trial: 9427777
Drug: D-galactose treatment
RxNorm normalized name: D(+)-Galactose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-galactose treatment
Trial: 8302686
Drug: Piperacillin 4
RxNorm normalized name: piperacillin 4000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin 4 g/70 kg
Trial: 8302686
Drug: Mezlocillin 5
RxNorm normalized name: Mezlocilline
DrugBank: Mezlocillin (DB00948)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mezlocillin 5 g/70 kg
Trial: 24942277
Drug: UFT/LV (UFT:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT/LV (UFT: 300‐600 mg/day and LV: 75 mg/day on days 1‐28 every 35 days; five courses)
Trial: 20804245
Drug: Telephone-administered cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-administered cognitive-behavioral therapy
Trial: 18723437
Drug: Erythromycin 250
RxNorm normalized name: erythromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 250 mg twice daily
Trial: 12830992
Drug: Valsartan (angiotensin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (angiotensin II antagonist)
Trial: 31418989
Drug: yohimbine 54
RxNorm normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: yohimbine 54 mg + hydrocortisone 10 mg
Trial: 27451294
Drug: 2 L
RxNorm normalized name: H-2 locus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 L of polyethylene glycol (PEG)
Trial: 21679977
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy for prostate cancer
Trial: 18507878
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (15 mg RRR-alpha-tocopherol/d)
Trial: 9407254
Drug: 6% glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% glucose and fructose solution at a rate of approximately 60 g/hr
Trial: 9407254
Drug: Placebo (artificially
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (artificially flavored solution)
Trial: 8218764
Drug: Metoclopramide (MCP)
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoclopramide (MCP) 10 mg, three daily doses, vo
Trial: 8218764
Drug: Cinitapride (CTP)
RxNorm normalized name: cinitapride
DrugBank: Cinitapride (DB08810)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinitapride (CTP) 1 mg, three daily doses, vo
Trial: 31927311
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of DBS
Trial: 8396101
Drug: Co-amoxiclav (13.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-amoxiclav (13.3 mg/kg tid for ten days)
Trial: 2939870
Drug: Prazosin 13.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin 13.8 mg twice daily
Trial: 31675478
Drug: H2-water (290
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2-water (290 mL)
Trial: 25864681
Drug: No bonding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No bonding agent used
Trial: 11207173
Drug: Hypo-osmolar ORS
RxNorm normalized name: Orserdu
DrugBank: Elacestrant (DB06374)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypo-osmolar ORS (224 mmol/l)